目的端粒酶在多种肿瘤细胞中高表达，可能是肿瘤分子靶向治疗的一个理想靶点。
Aim Telomerase is highly expression in most tumor cells, and it is an ideal target for cancer molecular targeting therapy.
分子靶向治疗是近年来肿瘤治疗的一个闪光点，凭着它的特异性和有效性，目前已成为国内外肿瘤治疗的研究热点。
Molecularly targeted therapy is a highlight of new pattern for cancer treatment, which has been a Research hot spot in recent years with its Specificity and Efficacy.
研究显示，PDCD4基因在肿瘤治疗中作为一种分子治疗靶向的可能性。
These studies indicated a potential value of PDCD4 as a molecular target in cancer therapy.
KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。
KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.
分子靶向治疗比传统的化疗特异性强、毒副反应小，将成为今后肿瘤治疗的新趋势。
Molecular targeted therapy has limited or nonexistent side effects on normal cells of the body, unlike traditional chemotherapy.
这种靶向性的策略包括目的基因对肿瘤细胞的靶向转移，目的基因在肿瘤细胞中的特异表达，以及基因修饰细胞分泌的肿瘤靶向治疗分子。
This can be achieved by tumor targeted gene transfer or tumor specific gene expression, as well as secretion of tumor targeted therapeutic molecules by autologous normal cells.
肿瘤靶向治疗中治疗靶点、靶向载体和效应分子的选择是关键。
In the research of tumor targeting therapy, how to select therapy target, tumor-homing vehicles and antitumor element is the most important.
英国利兹大学的一项研究已经发现，通过靶向一个分子帮助细胞恢复他们的DNA，可能为一些侵袭性脑肿瘤带来新的治疗方式。
Targeting a molecule that helps cells repair their DNA could lead to a new treatment for some aggressive brain tumours, a University of Leeds study has found.
近年来国际上对其治疗的研究已主要集中在分子水平上，如抗肿瘤坏死因子（TNF） 抗体，T细胞靶向药物等。
Recently some new medicines as anti-TNF bodies and T cell directed agents are used in treatment.
结论：化学合成的小肽p5有望作为先导分子，在以KDR为靶点的肿瘤靶向治疗中得到应用。
Conclusion: the peptide P5 that home to KDR expressed on tumor vasculature may also be useful in targeting therapies specifically to tumors.
这些多肽序列在肿瘤血管靶向治疗，肿瘤血管特异性分子标志物试剂的研制方面将具有巨大的潜在价值。
These polypeptide sequences have great potential in the targeting treatment of tumor veins and the development of the symbol reagent of the specific molecule of the tumor veins.
应用伊马替尼对包含该突变体的肿瘤进行分子靶向治疗，多数患者表现为药物抵抗。
The most GISTs are drug-resistant when be treated with imatinib which is a molecular targeted drug.
甚至有人提出OPN可以作为肿瘤分子靶向治疗的一个靶点。
Even someone posed that OPN can be regarded as a target for molecular targeted therapy of many kinds of tumors.
微创治疗联合生物治疗和分子靶向治疗的新模式将成为新世纪肿瘤治疗的重要组成部分。
The new mode of combined minimally invasive therapy with bio-immunotherapy is expected to be the most important part of cancer treatment in the 21st Century.
微创治疗联合生物治疗和分子靶向治疗的新模式将成为新世纪肿瘤治疗的重要组成部分。
The new mode of combined minimally invasive therapy with bio-immunotherapy is expected to be the most important part of cancer treatment in the 21st Century.
应用推荐